Sánchez MD, López CJ

Language: Spanish
References: 16
Page: 129-139
PDF size: 409.14 Kb.

ABSTRACT

Cutaneous lupus erythematosus includes a variety of lupus erythematosus-specific skin lesions that are subdivided into three categories: acute lupus erythematosus, subacute lupus erythematosus and chronic lupus erythematosus, based on clinical morphology, average duration of skin lesions as well as histopathologic and immunologic examinations. Such extensive clinical heterogeneity presents a challenge to physicians in terms of clinical classification, establishing a diagnosis and implementing a therapy. Generally, the treatment for cutaneous lupus erythematosus is based on strict photoprotection and antimalarials as first-line of systemic therapy. These drugs help to control the disease in 75% to 95% of the cases. Nevertheless the remaining percentage of cases will require another type of immunomodulating or immunosupressing systemic therapy that may have variable efficacy and will not be exempt of side effects.

REFERENCES

1. Chang A, Piette E, Foering K, et al. Response to Antimalarial Agents in Cutaneous Lupus Erythematosus. Archives of Dermatology. 2011; 147(11): 1261-1267.

2. Ezra N, Jorizzo J. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. Clinical and Experimental Dermatology. 2011; 37, 327-334.

3. Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: Diagnosis and Management. American Journal of Clinical Dermatology. 2003, 4(7): 449-465.

4. Gonzalez B, García I, Oliveira R et al. Quinacrine in the treatment of cutaneous lupus erythematosus: Practical Aspects and a case series. Actas Dermosiliográficas. 2010; 101 (1): 54-58.

5. Hansen C, Dahle K. Cutaneous lupus erythematosus. Dermatologic Therapy. 2012; Vol 25: 99-111.

6. Ikeda T, Kanazawa N, Furukawa F. Hydroxychloroquina administration for Japanese lupus erythematosus in Wakayama: A pilot study. The Journal of Dermatology. 2012; 39: 531-535.

7. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: Update of therapeutic options, Part I. Journal of the American Academy of Dermatology. 2011; 65:e179-193.

8. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: Update of therapeutic options, Part II. Journal of the American Academy of Dermatology. 2011; 65:e195-213.

9. Lee H, Sinha A. Cutaneous lupus erythematosus: Understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies. Autoinmunity. 2006, 39(6): 433-444.

10. Piette E, Foering K, Chang A , et al. Impact of smoking in Cutaneous Lupus Erythematosus. Archives of Dermatology. 2012; 148(3) 317-322.

11. Sticherling M, Bonsmann G, Kuhn A. Diagnostic approach and treatment of cutaneous lupus erythematosus. Journal of the German Society of Dermatology. 2008, 6: 48-61.

12. Terao M, Matsui S, Katayama I. Two cases of refractory discoid lupus erythematosus successfully treated with topical tocoretinate. Dermatology Online Journal. 2011; 17(4):15.

13. Walling H, Sontheimer R. Cutaneous lupus erythematosus: Issues in diagnosis and treatment. American Journal of Clinical Dermatology. 2009, 10(6): 365-381.

14. Werth Victoria. Clinical manifestations of cutaneous lupus erythematosus. Autoimmnunity Reviews. 2005, (4) 296-302.

15. Wolff K, Johnson R. Fitzpatrick, Atlas en color y sinopsis de dermatología clínica. 6ᵃ edición. Buenos Aires: Editorial Médica Panamericana, 2010: pág 377.

16. Wozniacka A, McCauliffe D. Optimal use of Antimalarials in Treating Cutaneous Lupus Erythematosus. American Journal of Clinical Dermatology. 2005, 6(1): 1-11.